Chronic lymphocytic leukaemia (supportive care)
Also known as: Chronic lymphocytic leukaemia, CLL, B-cell chronic lymphocytic leukaemia, B-CLL
Chronic lymphocytic leukaemia (CLL) is a malignancy of mature B-lymphocytes, characterised by a heterogeneous clinical course. Haematology-led management comprises active surveillance or therapeutic intervention based on disease kinetics, symptomatology, and complications. Supportive care focuses on fatigue, infection risk, haemorrhagic diathesis, nutritional status, and psychological morbidity. Traditional Chinese Medicine (TCM) assessment may offer an adjunctive framework for symptom management; however, these patterns do not correlate with oncological staging or therapeutic response. The cited abstract addresses thromboprophylaxis in acute lymphoblastic leukaemia during asparaginase therapy, not CLL, and provides no evidence for acupuncture or herbal medicine in CLL management. All interventions necessitate coordination with the primary oncology team, review of current haematological parameters, and screening for drug-herb interactions; they must not defer conventional standard of care.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Adhere to all haematological consultations and the prescribed surveillance or therapeutic protocol, irrespective of perceived wellness.
- •Balance low-impact physical activity with sufficient rest; report any sustained decline in functional performance status rather than persisting with exertion.
- •Maintain rigorous food hygiene standards and regular nutritional intake; request dietician referral for involuntary weight loss, dysphagia, or inadequate caloric intake.
- •Review the immunisation schedule and infection-prevention strategies with the medical team; maintain tobacco abstinence and ensure all supplementary products undergo clinical review prior to administration.
Cautions & Contraindications
- •Defer needling with active bleeding or clinically significant thrombocytopenia until the haematology team has reviewed current results and approved a plan. Anticoagulants and bleeding-prone therapies require individual assessment. Source [1] concerns bleeding and thromboprophylaxis in ALL, not acupuncture safety or CLL platelet thresholds.[]
- •Defer acupuncture during fever, suspected infection or clinically significant neutropenia pending oncology advice. This is a general procedural precaution and is not evaluated by supplied source [1].[]
- •Do not prescribe herbs without a complete medicine and supplement review, including anticoagulants and targeted cancer treatments; do not initiate or stop thromboprophylaxis on this guide's basis. Source [1] reports uncertain thromboprophylaxis evidence in ALL and does not evaluate herbal interactions or CLL care.[]
When to reassess or seek care again
If the oncology team agrees to a symptom-focused trial, review after 2–4 weeks or sooner if symptoms worsen. Record baseline and follow-up fatigue and distress scores from 0–10, sleep duration, appetite, bowel symptoms and ability to perform usual activities. Check for bruising, bleeding, infection and medicine changes at every visit. Stop or revise care if there is no meaningful improvement, any adverse effect or deterioration. Refer promptly for new systemic symptoms, falling function or worsening blood counts; symptom changes must not be interpreted as cancer response.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- The Cochrane database of systematic reviews · 2020
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
